Is Legend Biotech (LEGN) Pricing Reflect Its Value After Recent Share Price Rebound?

• If you are wondering whether Legend Biotech's share price reflects its underlying value, this article breaks down what the current market price may be implying about the company.
• The stock closed at US$19.05, with returns of 8.2% over the last week and 3.3% over the last month. The 1 year return stands at a 42.7% decline and the 3 year return at a 60.5% decline.
• Recent coverage around Legend Biotech has focused on its position in the biotech space and how investors are reassessing risk and reward in the sector. This context provides a backdrop for the recent short term share price moves and helps frame questions about what is already incorporated into the current valuation.
• Legend Biotech currently has a valuation score of 4/6, which reflects the number of checks where the stock screens as undervalued. Next is a closer look at how different valuation methods approach the company and a broader way to think about value that brings all of those pieces together.

Find out why Legend Biotech's -42.7% return over the last year is lagging behind its peers.

Approach 1: Legend Biotech Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today using a required rate of return. The goal is to translate those future dollars into a single present value figure per share.

For Legend Biotech, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of $133.48 million, so the starting point is negative. Analysts provide explicit free cash flow estimates for the next few years, and Simply Wall St then extrapolates further out to create a 10 year path.

Within that path, projected free cash flow reaches $1.00 billion in 2030, with intermediate years ranging from about $134.31 million in 2026 to $892.11 million in 2029. Each of these projected cash flows is discounted back to today, producing a total estimated fair value of $128.83 per share.

Compared with the recent share price of $19.05, the DCF output suggests the stock is about 85.2% below this intrinsic value. This points to a large valuation gap based on these assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Legend Biotech is undervalued by 85.2%. Track this in your watchlist or portfolio, or discover 63 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Legend Biotech.

Approach 2: Legend Biotech Price vs Sales

Price-based multiples are often used for companies where earnings are not yet positive, and in those cases P/S can be more useful than P/E because it focuses on revenue rather than profit. For profitable companies, the level of the multiple that investors are usually comfortable with is influenced by how much growth they expect and how much risk they see in the business.

Legend Biotech currently trades on a P/S ratio of 3.42x. This sits below the Biotechs industry average P/S of 10.64x and below the peer group average of 8.03x. On the surface, that suggests the market is assigning a lower revenue multiple compared with many similar companies.

Simply Wall St’s Fair Ratio for Legend Biotech is 3.26x. This is a proprietary estimate of what the P/S might reasonably be, given factors such as earnings growth, industry, profit margins, market cap and specific risks. Because it folds these elements into a single figure, it can be more tailored than a simple comparison with peers or the broad industry, which may not share the same risk and growth profile.

The current P/S of 3.42x is slightly above the Fair Ratio of 3.26x, so the shares screen as modestly overvalued on this basis.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Legend Biotech Narrative

Earlier the point was made that there is an even better way to understand valuation, so here is Narratives, a simple way for you to link your view of Legend Biotech’s story to a financial forecast and a fair value, then compare that fair value with the current price to decide whether you see the shares as attractive or expensive.

On Simply Wall St’s Community page, Narratives let you set assumptions for future revenue, earnings and margins. Instead of just accepting one DCF or P/S output, you can say, for example, that you side with a more cautious view where fair value sits around US$21 a share, or a more optimistic view closer to US$91 a share, and immediately see how that stacks up against the latest trading price.

Because these Narratives are updated when new news, earnings or guidance are added to the platform, your Legend Biotech story is not fixed. You can quickly adjust your assumptions as information changes rather than rebuilding a model from scratch each time.

Do you think there's more to the story for Legend Biotech? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com